BidaskClub upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.
A number of other research analysts have also issued reports on ZIOP. HC Wainwright set a $6.00 target price on ZIOPHARM Oncology and gave the company a buy rating in a research report on Tuesday, November 13th. Raymond James upgraded ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 target price on the stock in a research report on Thursday, November 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $5.33.
Shares of NASDAQ:ZIOP opened at $3.10 on Friday. ZIOPHARM Oncology has a 1 year low of $1.90 and a 1 year high of $5.24. The company has a market cap of $455.61 million, a PE ratio of -5.85 and a beta of 1.85.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Recommended Story: Systematic Risk and Investors
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.